Loading...
ASH congresses2022-02-16T15:57:20+01:00

ASH 2021 – virtual

Lecture Board: Othman Al-Sawaf, MD – Germany; Jorge J. Castillo, MD – USA; Wojciech Jurczak, MD, PhD – Poland; Amitkumar Mehta, MD – USA

Preface

Preface – ASH 2021 Amitkumar Mehta, MD, Division of Hematology and Oncology, University of Alabama at Birmingham, USA Dear Colleagues, The 63rd Annual Meeting of the American Society of Hematology (ASH) took place as a hybrid event that hosted participants both online and on-site in ­Atlanta, Georgia, USA.

Determining first-line CLL/SLL treatment strategies with optimized efficacy and safety

Determining first-line CLL/SLL treatment strategies with optimized efficacy and safety GAIA: FCR compared to targeted regimens The international, randomized, phase III GAIA/CLL13 study was conducted to identify the optimal time-limited first-line treatment regimen for fit patients with chronic lymphocytic leukemia (CLL). Standard chemoimmunotherapy (CIT) consisting of fludarabine, cyclophosphamide and rituximab (FCR; patients ≤ 65 years) or bendamustin plus rituximab (BR; patients &gt

Management of patients with relapsed/refractory CLL: what is new?

Management of patients with relapsed/refractory CLL: what is new? VISION: stop-start approach with ibrutinib/venetoclax The optimal novel-agent approach for patients with chronic lymphocytic leukemia (CLL) is subject to research. Targeted therapies have become the undisputed standard of care in both relapsing/refractory and treatment-naïve settings. The choice of regimen remains, however, disputable. Continuous BTK inhibition confers the risk of cumulative toxicity and acquired resist

Mantle cell lymphoma: refining clinical outcomes beyond the current boundaries

Mantle cell lymphoma: refining clinical outcomes beyond the current boundaries Parsaclisib: primary analysis of CITADEL-205 Targeted therapies including BTK inhibi­tors are used in the second- and later-line treatment of patients with mantle cell lymphoma (MCL), although intolerance and treatment failure are common, with poor survival outcomes in the relapsed and refractory setting [1, 2]. This highlights the need for novel agents such as the potent and highly selective next-generatio

Marginal zone lymphoma: PI3Kδ inhibition and beyond

Marginal zone lymphoma: PI3Kδ inhibition and beyond CITADEL-204: parsaclisib in BTK-inhibitor–naïve patients First-line treatment for patients with marginal zone lymphoma (MZL) typically includes anti-CD20-based regimens that generally evoke high response rates [1, 2]. However, in most cases, serial relapses eventually require several lines of therapy. The phase II CITADEL-204 trial evaluated the highly selective, next-generation PI3Kδ inhibitor parsaclisib in patients with relapsed/r

Phase II data on novel BTK inhibitors for patients with Waldenström’s macroglobulinemia

Phase II data on novel BTK inhibitors for patients with Waldenström’s macroglobulinemia Orelabrutinib: rapid and lasting responses Second-generation BTK inhibitors such as orelabrutinib and tirabrutinib are currently being evaluated in the treatment of Waldenström’s macroglobulinemia (WM). Orelabrutinib is a BTK inhibitor with excellent target selectivity and almost 100 % BTK occupancy [1]. At ASH 2021, Zhou et al. reported the results for 47 patients with relapsed/refractory WM who r

Promising novel approaches in various B-cell malignancies

Promising novel approaches in various B-cell malignancies POLARIX: polatuzumab vedotin in DLBCL For more than 20 years, the R-CHOP regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone has been the standard of care in the first-line treatment of diffuse large B-cell lymphoma (DLBCL).

DOWNLOADS

All downloads from ASH 2021

ASH 2021 virtual - Slidekit

Slidekit BTK inhibition and BCL2 inhibition in CLL/SLL and other B-cell malignancies

ASH 2021 virtual - Congress Report

Full report (english)

EXPERT VIDEOS

All videointerviews from ASH 2021

Constantine Tam gives an overview of the results obtained by the SEQUOIA trial, the advantages and disadvantages of BTKi and BCL2i 1L therapy versus their drawbacks and explains which CLL-patients might benefit from BTK inhibitor monotherapy and who might be better off receiving combination treatment including a BTK inhibitor and how novel BCL2 inhibitors improve CLL treatment compared to the standard agent venetoclax.

Jennifer A. Woyach explains which factors need to be considered when choosing the frontline regimen for patients with early-stage CLL, how resistance to BTK inhibition can be tackled in later lines, if chemoimmunotherapy still has a role in the treatment of CLL and highlights the most interesting findings on the management of treatment-naïve CLL patients.

 

Paolo Ghia highlights what modern targeted agents can achieve in terms of undetectable minimal residual disease in the management of patients with CLL and important methodological recommendations to ensure correct assessment of TP53 and IGHV mutational status. He explains how the three epigenetic subgroups (m-CLL, n-CLL, i-CLL) are related, what effect a thorough immunogenetic analysis has on the risk stratification of patients with CLL and gives an overview about the most interesting findings on the management of pretreated CLL patients.

Alessandra Tedeschi depicts her personal highlights reported at ASH 2021 and explains the results obtained in treatment-naïve CLL patients with a deletion of 17p in the SEQUOIA study. The influence of age, fitness, and concomitant medications on the management and outcomes of patients with CLL treated with targeted agents, the most notable progress in B-cell malignancies over the last years and the role of BTK inhibitors in the treatment of patients with Waldenström’s macroglobulinemia are summarized, too.

ASH 2020 – virtual

Lecture Board: Paul Barr, MD; Chan Cheah, MBBS; Paolo Ghia, MD, PhD; Preetesh Jain, MD, PhD; Stephen Opat, MD; Kerry Rogers, MD; Alessandra Tedeschi, MD
Medical Writer: Dr. Judith Moser

Preface – ASH 2020

Preface – ASH 2020 Heinz Ludwig, MD, Director of the Wilhelminen Cancer Research Institute, Department of Medicine I, Center for Oncology, Hematology and Palliative Care, Wilhelminen Hospital, Vienna, Austria Dear Colleagues, The ASH Annual Meeting and Exposition is the premier event for presentation of novel data on malignant and non-malignant hematologic diseases, attracting up to 30,000 specialists from all over the world.

What is new in Waldenström’s macroglobulinemia?

What is new in Waldenström’s macroglobulinemia? Constitutive activation of the Bruton’s tyrosine kinase (BTK) pathway has been shown to induce malignant cell survival in patients with Waldenström’s macroglobulinemia (WM) [1, 2].

Management of CLL patients: BTK inhibition and beyond

Management of CLL patients: BTK inhibition and beyond BTK inhibitors, the Bcl-2 inhibitor venetoclax and anti-CD20 antibodies such as obinutuzumab have dramatically changed the therapeutic landscape of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Advancing treatment in patients with mantle cell lymphoma

Advancing treatment in patients with mantle cell lymphoma Update on acalabrutinib monotherapy High relapse rates after standard-of-care regimens in the frontline setting are typical of mantle cell lymphoma (MCL), which is an aggressive, rare, B-cell Non-Hodgkin lymphoma [1-4].

Finding the way among a multitude of targets and regimens

Finding the way among a multitude of targets and regimens Stephen Opat, MD,  School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia Under which conditions might patients with chronic lymphocytic leukemia achieve long-term treatment-free remission?

Bone marrow microenvironment: culprit and target

Bone marrow microenvironment: culprit and target  Jorge J. Castillo, MD, Dana-Farber Cancer Institute, Boston, USA Apart from factors such as genetic events that contribute to the malignant transformation in Waldenström’s macroglobulinemia (WM), the bone marrow microenvironment has been identified as a crucial player in WM disease progression [1].

序言

序言 Heinz Ludwig, MD 威廉明娜癌症研究所主任 肿瘤学、血液学和姑息护理中心医药I部 奥地利维也纳威廉明娜医院 亲爱的同事们, ASH年会暨展览会是介绍恶性及非恶性血液病相关新数据的重要活动,吸引了来自全球多达30,000名专家。

华氏巨球蛋白血症领域有何新进展?

华氏巨球蛋白血症领域有何新进展? 研究表明,布鲁顿酪氨酸激酶(BTK)途径的组成性激活可诱导华氏巨球蛋白血症(WM)患者的恶性细胞存活[1,2]。该疾病是基于分泌IgM的克隆性淋巴浆细胞在骨髓和髓外部位的积累[3]。MYD88L265P突变(> 90 %的病例)和CXCR4WHIM样突变(大约27 %的病例)已被确定为WM的病理学标志 [4-6]。

CLL患者管理:BTK抑制及其他

CLL患者管理:BTK抑制及其他 BTK抑制剂、Bcl-2抑制剂维奈托克(venetoclax)和诸如阿托珠单抗(obinutuzumab)等抗CD20抗体已大大改变了慢性淋巴细胞性白血病(CLL)/小淋巴细胞性淋巴瘤(SLL)的治疗前景。依鲁替尼,作为BTK抑制剂类的第一代代表,是主要治疗手段,但其明显的缺点导致引入了第二代药物。

从多种角度尝试治疗边缘区淋巴瘤

从多种角度尝试治疗边缘区淋巴瘤 约10 %的非霍奇金淋巴瘤被分类为边缘区淋巴瘤(MZL)[1]。这是一种异质性恶性肿瘤,由次级淋巴滤泡边缘区域的记忆B细胞引起,具有三种主要的亚型(即结外、结内、脾脏)[2,3]。

套细胞淋巴瘤患者中的先进疗法

套细胞淋巴瘤患者中的先进疗法 阿卡替尼单药疗法的最新进展 套细胞淋巴瘤(MCL)的典型特征在于一线标准护理方案后的高复发率,它是一种侵袭性、罕见的B细胞非霍奇金淋巴瘤[1-4]。基于单组、开放标签、多中心、II期ACE-LY-004研究,第二代高选择性BTK抑制剂阿卡替尼已在美国被批准用于治疗经过≥1种先前疗法的MCL患者[5] 。

在众多靶标和方案中寻找出路

在众多靶标和方案中寻找出路 专访:Stephen Opat, MD, 澳大利亚墨尔本莫纳什大学莫纳什健康临床科学学院 Stephen Opat, MD, 澳大利亚墨尔本莫纳什大学 莫纳什健康临床科学学院 慢性淋巴细胞性白血病患者在哪种情况下可以实现长期无治疗的缓解? 在这里我想强调两个因素。第一个因素涉及有利的疾病生物学。免疫球蛋白基因突变或者缺乏TP53突变或17p缺失的患者更有可能获得无治疗的缓解。

PD-1抑制和(非)霍奇金淋巴瘤:在新兴领域的结果可期

PD-1抑制和(非)霍奇金淋巴瘤:在新兴领域的结果可期 纳武单抗(Nivolumab)加BV用于MGZL治疗 纵隔灰区淋巴瘤(MGZL)是一种非常罕见的非霍奇金淋巴瘤,主要出现在年轻男性中[1]。该病表现出在结节性硬化经典霍奇金淋巴瘤(cHL)与原发性纵隔B细胞淋巴瘤(PMBL)之间的过渡特征[2, 3]。

骨髓微环境:元凶和靶标

骨髓微环境:元凶和靶标 Jorge J. Castillo, MD 美国波士顿 达纳-法伯癌症研究所 除了诸如引起华氏巨球蛋白血症(WM)恶性转化的遗传事件等因素外,骨髓微环境还被认为是WM疾病进展的关键因素[1]。同样,它对于多发性骨髓瘤(MM)的出现和进展似乎必不可少,并且是MM患者难以治愈且不可避免会复发的重要原因[2]。大约在15年前,在骨髓微环境的背景下对恶性细胞生长的描述就已成为研究的重点,因为这可能实现针对MM和WM设计更有效的治疗策略。

DOWNLOADS

All downloads from ASH 2020

ASH 2020 virtual - Slidekit

Slidekit BTK inhibition in B-Cell Malignancies

ASH 2020 virtual - Congress Report

Full report (english)

EXPERT VIDEOS

All videointerviews from ASH 2020

Steven P. Treon explains about innovative approaches in the treatment of Waldenström’s macroglobulinemia, future aspects and the successful use of BTK inhibition within niche groups of patients with WM, and potential benefits of BTK inhibitors regarding COVID-19 complications.

Jorge Castillo relates to recent developments with respect to follicular lymphoma, multiple myeloma and Waldenström’s macroglobulinemia, current insights into CAR-T cell therapy in the setting of multiple myeloma, and the future of anti-CD38 antibody treatment in patients with Waldenström’s macroglobulinemia.

Alessandra Tedeschi summarizes the results from the MAGNOLIA and iNNOVATE trials, relates to recent advances in the management of marginal zone lymphoma and discusses the effect of the introduction of BTK inhibition on the prognosis of patients with Waldenström’s macroglobulinemia.

Stephen Opat discusses the requirements for treatment-free long-term remission in the setting of CLL and talks about the future of BTK inhibitors and promising combinations in B-cell malignancies in general, as well as the strengths and limitations of immune checkpoint inhibitors.